BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33843161)

  • 1. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.
    Xiang WL; Cheng JJ; Wu LP; Chen BY; Li WX; Qiu DY; Zhang W; Ge FH; Chen D; Wang Z
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):955-960. PubMed ID: 33843161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.
    Hähnel V; Peterhoff D; Bäuerlein V; Brosig AM; Pamler I; Johnson C; Bica A; Totir M; Ossner T; Stemmer B; Toelge M; Schütz A; Niller HH; Schmidt B; Wagner R; Gessner A; Burkhard R; Offner R
    PLoS One; 2020; 15(12):e0243967. PubMed ID: 33351831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Responses in COVID-19: A Review.
    Chvatal-Medina M; Mendez-Cortina Y; Patiño PJ; Velilla PA; Rugeles MT
    Front Immunol; 2021; 12():633184. PubMed ID: 33936045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
    Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
    Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
    Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
    Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
    Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.
    Verkerke H; Saeedi BJ; Boyer D; Allen JW; Owens J; Shin S; Horwath M; Patel K; Paul A; Wu SC; Wang J; Ho A; Maier CL; Zerra PE; Chonat S; Arthur CM; Roback JD; Neish AS; Lough C; Josephson CD; Stowell SR
    Transfusion; 2021 Jun; 61(6):1740-1748. PubMed ID: 34041759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
    Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A
    N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.
    Zeng F; Dai C; Cai P; Wang J; Xu L; Li J; Hu G; Wang Z; Zheng F; Wang L
    J Med Virol; 2020 Oct; 92(10):2050-2054. PubMed ID: 32383183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.
    Liu M; Chen Z; Dai MY; Yang JH; Chen XB; Chen D; You H; Guo X; Leng Y; Yu L; Zhang ML; Wu X; Yang J; Gao C; Tenen DG; Chai L; Ai F
    Transfusion; 2020 Oct; 60(10):2210-2216. PubMed ID: 32770691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.